Provided by Tiger Fintech (Singapore) Pte. Ltd.

Caribou Biosciences

1.26
+0.170015.60%
Post-market: 1.280.0200+1.59%19:54 EDT
Volume:2.03M
Turnover:2.53M
Market Cap:117.19M
PE:-0.78
High:1.33
Open:1.11
Low:1.11
Close:1.09
Loading ...

Truist Removes Price Target on Caribou Biosciences, Keeps Buy Rating; Price Target Was $19

MT Newswires Live
·
20 Mar

Caribou Biosciences Price Target Maintained With a $9.00/Share by HC Wainwright & Co.

Dow Jones
·
19 Mar

Analysts Offer Insights on Healthcare Companies: Ascend Wellness Holdings LLC (OtherAAWH), Bristol-Myers Squibb (BMY) and Caribou Biosciences (CRBU)

TIPRANKS
·
13 Mar

RBC Cuts Price Target on Caribou Biosciences to $11 From $14, Keeps Outperform, Speculative Risk

MT Newswires Live
·
11 Mar

Caribou Biosciences, Inc. (CRBU) Reports Q4 Loss, Lags Revenue Estimates

Zacks
·
11 Mar

Caribou Biosciences Inc - Expects $249.4 Mln in Cash, Cash Equivalents to Fund Operations Into H2 2026

THOMSON REUTERS
·
11 Mar

Caribou Biosciences Q4 2024 GAAP EPS $(0.39) Beats $(0.42) Estimate, Sales $2.08M Miss $2.11M Estimate

Benzinga
·
11 Mar

Press Release: Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Dow Jones
·
11 Mar

Caribou Biosciences, Inc. (NASDAQ:CRBU) is a favorite amongst institutional investors who own 62%

Simply Wall St.
·
25 Feb

Caribou Biosciences to Participate in Upcoming Investor Conferences

GlobeNewswire
·
19 Feb

Caribou Biosciences Advances CAR-T Therapy Trials

TIPRANKS
·
13 Jan

Caribou Biosciences Starts Phase 1 Trial for Lupus Drug Candidate

MT Newswires Live
·
13 Jan

Caribou Biosciences initiates CB-010 GALLOP Phase 1 trial in lupus

TIPRANKS
·
13 Jan

Caribou Biosciences Initiates the CB-010 Gallop Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025

THOMSON REUTERS
·
13 Jan

Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025

GlobeNewswire
·
13 Jan

Caribou Biosciences Is Maintained at Buy by B of A Securities

Dow Jones
·
08 Jan

BofA Securities Cuts Price Target on Caribou Biosciences to $11 From $13, Maintains Buy Rating

MT Newswires Live
·
07 Jan

Caribou Biosciences price target raised to $34 from $26 at Brookline

TIPRANKS
·
06 Jan

Caribou Biosciences Names Sri Ryali CFO

MT Newswires Live
·
02 Jan

Caribou Biosciences Appoints New CFO Amid Clinical Advancements

TIPRANKS
·
02 Jan